Page last updated: 2024-12-06

siccanin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Siccanin is a natural product with a complex structure, featuring a unique bicyclic ring system. It has been isolated from the fungus *Aspergillus fumigatus*. The compound exhibits various biological activities, including antifungal, antibacterial, and anti-inflammatory properties. Researchers are interested in exploring its potential therapeutic applications due to its promising activities against pathogenic organisms and its potential to modulate inflammatory responses.'

siccanin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71902
CHEMBL ID3989494
CHEBI ID32128
MeSH IDM0042137

Synonyms (26)

Synonym
nsc-135048
siccanin
siccaninum
sicanina
siccanine
siccanine [inn-french]
nsc 135048
sicanina [inn-spanish]
siccanin [inn:jan]
siccaninum [inn-latin]
unii-l702s858z6
l702s858z6 ,
13h-benzo(a)furo(2,3,4-mn)xanthen-11-ol, 1,2,3,4,4a,5,6,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-, (4as-(4aalpha,6aalpha,11balpha,13ar*,13balpha))-
(13as)-1,2,3,4,4abeta,5,6,6a,11bbeta,13bbeta-decahydro-4,4,6abeta,9-tetramethyl-13h-benzo(a)furo(2,3,4-mn)xanthen-11-ol
siccanin [who-dd]
siccanin [mi]
siccanin [jan]
siccanin [mart.]
siccanin [inn]
CHEBI:32128
CHEMBL3989494
(1s,4r,12s,15s,20s)-8,12,16,16-tetramethyl-3,11-dioxapentacyclo[10.7.1.01,15.04,20.05,10]icosa-5,7,9-trien-6-ol
Q27282791
AKOS040749499
HY-106371
CS-0025676
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antifungal drugAny antifungal agent used to prevent or treat fungal infections in humans or animals.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic heteropentacyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.53 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]